NDNazila Dalir

Nazila Dalir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nazila Dalir has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recognizing a duplicated inferior vena cava during radical nephrectomy for papillary renal cell carcinoma: A case report

    by Muhammad Wajid Siddique, Muhammad Waqas, Muhammad Hanzla Shahzad, Muhammad Hassaan Javaid, Nazila Dalir

  • Open Access

    Giant Chylous Mesenteric Cyst Requiring Segmental Small Bowel Resection in a Young Adult: A Case Report

    by Muhammad Wajid Siddique, Muhammad Hanzla Shahzad, Rabia Zameer, Hassaan Javaid, Elsa Obaid, Muhammad Abdullah Cheema, Nazila Dalir

    We report a 21‐year‐old male with a giant 20 × 20 × 15‐cm chylous mesenteric cyst. Such cysts present nonspecifically and pose diagnostic and surgical challenges. When a cyst is intimately attached to bowel and shares its mesenteric vascular supply, segmental bowel resection with complete cyst removal may be necessary because safe separation is not possible.

  • Open Access

    Beyond conventional metastatic patterns: a case report of isolated omental metastasis from high-risk prostate adenocarcinoma

    by Muhammad Wajid Siddique, Muhammad Hanzla Shahzad, Mahnoor Shah, Taha Alam, Nazila Dalir, Muhammad Waqas

    Background: Peritoneal and omental metastasis from prostate adenocarcinoma is rare and usually occurs in the setting of widespread disease. Isolated peritoneal involvement without skeletal or nodal disease is uncommon, and the mechanism of spread is not well understood. Case presentation: A 64-year-old man presented with lower urinary tract symptoms and was diagnosed with high-risk prostate adenocarcinoma (Gleason 4 + 5=9, WHO Grade Group 5) after transurethral resection of the prostate (TURP); post-operative prostate-specific antigen (PSA) was 7.8 ng/mL, and the pre-operative work-up was not available. Staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) showed locally invasive disease extending into the seminal vesicles and bladder base, without nodal or distant metastasis. He was treated with hormonal therapy and external beam radiotherapy, achieving a PSA nadir of 0.35 ng/mL. Despite a subsequent rise in PSA, a surveillance PSMA PET/CT was negative for recurrence. PSA continued to rise progressively, reaching 59.17 ng/mL, with new lower urinary tract symptoms. Repeat PSMA PET/CT showed ascites and diffuse PSMA-avid omental caking with peritoneal fat stranding, without local recurrence, lymphadenopathy, or osseous metastasis. Image-guided tru-cut biopsy of the omentum confirmed metastatic carcinoma compatible with the known prostatic primary. He was started on docetaxel with continued luteinizing hormone-releasing hormone (LHRH) therapy, abiraterone, and prednisolone, and remains under oncological surveillance. Conclusion: Peritoneal and omental recurrence can occur after TURP-diagnosed prostate cancer without involvement of the usual sites of spread, and a TURP-related iatrogenic contribution cannot be excluded. A negative PSMA PET/CT does not exclude progression; in selected patients with a marked, sustained PSA rise and new symptoms, repeat imaging may be considered when it is likely to alter management, and histopathological confirmation is required when an atypical metastatic site is suspected.

  • Open Access

    Differential impact of catheter ablation across heart failure phenotypes in atrial fibrillation: a grade assessed systematic review and meta-analysis

    by Faizan Ahmed, Ayesha Zulfiqar, Mohamed Nasser Elshabrawi, Omama Ayatullah, Sheraz Qasim, Hira Sarfraz, Haris Bin Tahir, Faseeh Haider, Maryam Fatima, Syed Ahmed Ali Shah, et al.

    Introduction: Atrial fibrillation (AF) is highly prevalent in heart failure (HF) and is linked to increased mortality and hospitalization in both preserved (HFpEF) and reduced ejection fraction (HFrEF). Catheter ablation (CA) has emerged as an effective rhythm-control strategy beyond medical therapy (MT), but phenotype-specific differences remain unclear. We compared the efficacy and safety of CA versus MT in AF with HFpEF or HFrEF. Methods: PubMed, Embase, Scopus, and Cochrane databases were searched through December 2025. Random-effects meta-analyses were conducted in R (version 4.5.3), reporting risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). Results: Fifteen studies involving 27,130 patients (CA: 13,579; MT: 13,551) were included. Catheter ablation significantly reduced overall all-cause mortality (RR 0.44), with a significant benefit in HFpEF (RR 0.44), whereas the reduction in HFrEF did not reach statistical significance (RR 0.53, 95% CI 0.21–1.38). Cardiovascular mortality and cardiovascular hospitalization were also reduced overall, without significant differences between HF phenotypes. Stroke and atrial arrhythmia recurrence were not significantly reduced in the primary analyses, and favorable findings observed in sensitivity analyses were considered exploratory . Catheter ablation significantly improved LVEF in HFrEF but not in HFpEF, while effects on exercise capacity and biomarkers varied across outcomes and phenotypes. Adverse events were comparable between treatment strategies. Conclusion: Catheter ablation was associated with favorable clinical outcomes compared with medical therapy in AF with HF; however, the magnitude and statistical certainty of benefit varied across heart failure phenotypes and outcomes.

  • Open Access

    Correlation of Echocardiographic Right Ventricular Functional Parameters with CMR-Derived Right Ventricular Ejection Fraction in Pulmonary Hypertension: A Systematic Review and Meta-Analysis

    by Faizan Ahmed, Ayesha Zulfiqar, Ramsha Ali, Syeda Simrah Shah, Saba Aliha, Muhammad Saad Khan, Sheraz Qasim, Maria Campwala, Maliha Khalid, Adiesh Sood, et al.

    Background: Pulmonary hypertension (PH) is associated with increased pulmonary arterial pressure and impairment of right ventricular (RV) function. Reliable characterization of RV performance is important for prognosis, risk assessment, and therapeutic planning. Cardiac magnetic resonance (CMR) is considered the reference technique for quantifying RV volumes and function, but its expense and limited availability can restrict routine implementation. Echocardiography is more widely accessible; however, the extent to which individual echocardiographic indices correspond with CMR-derived RV ejection fraction (RVEF) remains incompletely defined. Objective: Our objective was to determine the correlation of RV fractional area change (RV-FAC), RV free-wall longitudinal strain (RV-FWLS), and RV global longitudinal strain (RV-GLS) with CMR-derived RVEF in individuals with PH. Methods: PubMed, Embase, ClinicalTrials.gov, Scopus, and the Cochrane Library were searched, yielding 404 records; six studies fulfilled the eligibility criteria. Studies were eligible when they enrolled patients with PH and provided extractable correlations between at least one prespecified echocardiographic measure and CMR-derived RVEF. Correlation coefficients were converted with Fisher’s z transformation, combined using common-effect and random-effects approaches, and then transformed back to correlation coefficients. Pooled mean RV-FAC was evaluated as a separate outcome. Between-study heterogeneity was quantified with I2 and τ2, with random-effects estimates emphasized for interpretation. Results: Each evaluated echocardiographic measure was positively correlated with CMR-derived RVEF. RV-FWLS had the largest pooled correlation and the greatest consistency (r = 0.79, 95% CI: 0.73–0.83; I2 = 0.0%). The pooled correlation for RV-GLS was 0.75 (95% CI: 0.60–0.85; I2 = 80.3%), while that for RV-FAC was 0.72 (95% CI: 0.61–0.80; I2 = 61.8%). The random-effects pooled mean RV-FAC was 31.10% (95% CI: 26.77–35.43), with substantial heterogeneity (I2 = 90.9%). Conclusions: RV-FWLS showed the highest numerical and most consistent association with CMR-derived RVEF, suggesting that it may serve as a useful non-invasive adjunct for RV assessment in PH, especially where CMR is not readily available. Larger studies using harmonized acquisition and analysis methods are required for confirmation.

  • Open Access

    Preoperative SGLT2 Inhibitor Use and Outcomes After Major Cardiac Procedures: A Propensity Score-Matched Analysis of the TriNetX Network

    by Mirza Muhammad Hadeed Khawar, Faizan Ahmed, Mohab Elnashar, Cheryl Vanessa Lewis, Minahil Shahid, Ali Asgher Shuja, Fatima Afzal, Naheed Sajjad, Muhammad Amir Khan, Meeran Atta, et al.

    Background/Objectives: Sodium–glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes in patients with diabetes, heart failure, and chronic kidney disease. Their association with perioperative outcomes after major cardiac procedures remains uncertain. Methods: In this retrospective cohort study using the TriNetX U.S. Collaborative Network, adults (≥18 years) undergoing cardiac procedures were identified. Patients with documented SGLT2 inhibitor use within 1 year before the index procedure were compared with non-users. Risk ratios (RR), risk differences, Kaplan–Meier survival curves, and Cox models were used for analysis. Results: Of 150,724 patients identified, 7526 propensity score-matched pairs were analyzed. The matched cohorts had a mean age of 65.8 ± 10.6 years and were predominantly male (70.5% male, 29.5% female). Preoperative SGLT2 inhibitor use was associated with significantly lower all-cause mortality at 30 days (1.3% vs. 2.3%; RR 0.566 [95% CI 0.443–0.722], p < 0.001), 90 days (2.2% vs. 3.4%; RR 0.643, p < 0.001), and 1 year (3.8% vs. 5.8%; RR 0.657, p < 0.001). MACE rates were similar between groups at all time points. Acute kidney injury at 30 days was lower with SGLT2 inhibitors (15.4% vs. 17.7%; RR 0.870, p < 0.001), whereas hospital admission rates were higher (76.4% vs. 68.7%; RR 1.111 [95% CI 1.089–1.133], p < 0.001). These associations were consistent in diabetes-only and obesity-only subgroups and in a 30-day landmark sensitivity analysis. Conclusions: In this large, contemporary, multi-institutional propensity score-matched cohort, preoperative SGLT2 inhibitor use was associated with reduced all-cause mortality and acute kidney injury after major cardiac procedures. These real-world findings support the conduct of dedicated randomized trials evaluating perioperative SGLT2 inhibitor therapy.

  • Open Access

    Management of two extremely aggressive signet ring cell colon carcinoma: a case series

    by Nazila Dalir, Glenn S Parker, Rachel Amanda Masia, Patricia Torres

    Signet ring cell carcinoma (SRCC) of the colon is a rare histologic subtype of colorectal cancer, accounting for <1% of cases, and is associated with aggressive clinical behavior and poor prognosis. We report two cases with advanced colonic SRCC. The first case involved a 58-year-old female with obstructing rectal SRCC and extensive pelvic invasion with adnexal metastasis. The second is a 45-year-old male with an obstructing splenic flexure SRCC and peritoneal dissemination, found to have microsatellite instability and multiple oncogenic alterations. Both cases required aggressive surgical intervention and illustrate the need for individualized, multimodal treatment strategies. Colonic SRCC is an uncommon but highly aggressive malignancy that frequently presents at an advanced stage. Early recognition, comprehensive pathologic and molecular evaluation, and coordinated multimodal management are critical to optimizing outcomes.

  • Open Access

    Late Presentation of Fetus in Fetu in a 10‐Year‐Old Boy

    by Kinza Akbar, Ali Raza, Aden Rehman, Muhammad Wajid Siddique, Tahreem Tariq, Muhammad Riaz Ul Haq, Nazila Dalir

    Fetus in fetu (FIF) is a rare congenital anomaly in which a dysmorphic, parasitic twin is retained within the body of its host twin. It typically presents in infancy, shows a slight male predominance, and is most often located in the retroperitoneum. Differentiating FIF from an abdominal teratoma on imaging is important, as the two entities can closely resemble one another. We report the case of a 10‐year‐old boy who presented with abdominal pain, low‐grade fever, and unintentional weight loss. Antenatal history was unremarkable. Abdominal examination revealed mild distension and left‐sided tenderness. Ultrasonography demonstrated an 8.5 × 10.4 × 11.1 cm mass‐like lesion in the left hypochondrium, and a provisional diagnosis of teratoma versus FIF was considered. Contrast‐enhanced computed tomography (CT) of the abdomen showed a large, well‐defined, heterogeneous mesenteric mass measuring 10.0 × 11.0 × 14.0 cm containing macroscopic fat, dense tooth–like calcifications, and osseous elements with attenuation of up to 1450 Hounsfield units, together with a well‐formed fetal skeleton. Serum tumor markers were within normal limits. A presumptive diagnosis of FIF, supported by imaging and by intraoperative findings that satisfied the Willis criteria, was made at exploratory laparotomy; histopathological confirmation could not be obtained because the specimen was inadequately fixed prior to processing, so a highly differentiated fetiform teratoma cannot be entirely excluded. The child remained well at last follow‐up, about 10 weeks after discharge; longer surveillance is required. This case illustrates that FIF, although classically a diagnosis of infancy, should remain in the differential diagnosis of a complex abdominal mass in an older child, and highlights the role of the Willis criteria, radiological correlation, and intraoperative findings when histopathology is unavailable.